CYDY takes a shot at the FDA: UK HIV pre-meeting is
CYDY takes a shot at the FDA: UK HIV pre-meeting is 350mg!!!
Well, well, some regulatory tactical wafare from Pourhassan. Very interesting.
CYDY is seeking a pre-approval meeting the the UK authorities for HIV combo therapy.
But there is a potentially significant twist.
CYDY will ask for approval for the 350 milligram dose in HIV combo therapy.
In the US, Cytodyn's HIV combo therapy BLA has been delayed because the FDA suggested that 700 milligrams might work better.
While this suggestion is generally favorable to Cytodyn as the FDA requested only safety studies on the 700 milligram dose and not re-doing the entire trial.
But now Pourhassan's patience appears to have been strained by the FDA's recent ask for more data on HIV combo when Cytodyn wanted a PDUFA data.
So Pourhassan's solution is to file for approval in the UK using the 350 milligram dose. All of the i's and t's have been dotted and crossed at 350 milligrams for well over a year.
Maybe UK will be receptive to the 350 mg dose and provide a quick approval?
6
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Hong Kong Wine & Dine Festival Returns This October HONG KONG, an anticipated gastronomic spectacle is set for the latter part of October. The Hong Kong Wine & Dine Festival will take place from 23 to 26 October 2025 at the iconic Central Harbourfront. This annual celebration is designed to showcase the best in culinary arts and exquisite wines, offering something special...
Continue Reading
Danaher Sets Date for Q3 2024 Earnings Conference Call Danaher Corporation (NYSE: DHR) has announced the date for its highly anticipated quarterly earnings conference call. This event is significant for investors and stakeholders who keep a close eye on the company's developments. Earnings Call Details The earnings call is set for an upcoming Tuesday morning, during which...
Continue Reading
UniQure Stock Reaches New Heights UniQure NV (QURE) has exciting news as its stock recently touched an impressive 52-week high of $18.5. This remarkable milestone is a testament to the company's resilient growth strategy and innovative advancements in the biotechnology industry. With a market capitalization reaching $885 million, the stock has seen an astonishing rise of...
Continue Reading
MedCana Enters Negotiations for Cannabis Supply Agreement MedCana, a prominent player in the pharmaceutical-grade cannabis landscape, is making headlines with an exciting new development from its subsidiary in Colombia. The company is set to negotiate a substantial supply agreement worth between $1.2 million and $2.4 million annually. This agreement marks a significant...
Continue Reading
Mouawad Teams Up with OCTA Properties for Luxe Residences OCTA Properties has been selected as the global licensee for residences branded by Mouawad, bringing the brand's legacy of timeless elegance into the realm of premium real estate. This partnership marks an exciting new chapter in Mouawad's prestigious journey in luxury development. A Landmark Collaboration Mouawad,...
Continue Reading